[Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review].

Zhirov, I V; Safronova, N V; Tereshchenko, S N

Zhirov, I V; Safronova, N V; Tereshchenko, S N.

Afiliação

Zhirov IV; Chazov National Medical Research Center of Cardiology.
Safronova NV; Russian Medical Academy of Continuous Professional Education.
Tereshchenko SN; Chazov National Medical Research Center of Cardiology.

Ter Arkh ; 95(9): 802-809, 2023 Nov 03.

Article em Ru | MEDLINE | ID: mdl-38158925

ABSTRACT

ABSTRACT

Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden. This review describes recent studies on the use of sacubitril/valsartan in heart failure patients with mildly reduced or preserved ejection fraction.

Assuntos

Insuficiência Cardíaca; Tetrazóis; Humanos; Volume Sistólico; Antagonistas de Receptores de Angiotensina/farmacologia; Valsartana; Insuficiência Cardíaca/diagnóstico; Insuficiência Cardíaca/tratamento farmacológico; Combinação de Medicamentos

Palavras-chave

heart failure; heart failure with mildly reduced ejection fraction; heart failure with preserved ejection fraction; sacubitril/valsartan; worsening heart failure

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetrazóis / Insuficiência Cardíaca Limite: Humans Idioma: Ru Revista: Ter Arkh Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google